Navigation Links
First head-to-head trials of once weekly Fosamax and Actonel therapies

The drug major Merck has launched the first two head-to-head clinical trials that compare the efficacy and tolerability of Fosamax (alendronate) once weekly 70mg and Actonel (risedronate) once-weekly 35mg. Fosamax and Actonel, both bisphosphonates indicated for the treatment of osteoporosis in post menopausal women are co-marketed by Aventis and Procter & Gamble through the Alliance for// Better Bone Health. The trial called FACTs(Fosamax Actonel Comparison Trials), is being sponsored by Merck as a US-based study, as well as an international study, each of which will examine approximately 800 post menopausal women with osteoporosis(defined by a bone mineral density (BMD) T-score of <=-2). The participants will be randomized in a one-to-one blinded fashion to either alendronate 70mg once weekly or risedronate 35mg once weekly. The trials will then evaluate and compare the effectiveness and tolerability of the 2 agents during 12 months of treatment in the post menopausal women with osteoporosis.


'"/>




Page: 1

Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. First human clone is near
4. First Artificial Heart patient has Major setback
5. WHO Declares Vietnam First Country to Control SARS
6. Russia Reports First SARS Case
7. Hope for First New Melanoma Treatment in Decades
8. First global SARS meet opens
9. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
10. Hyderabad To Have Asia’s First Catheter Making Uni
11. First telesurgery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") ... Surgical facility in Las Piedras, Puerto Rico ... and blades. ... the facility sustained minor structural damage, temporary loss of ... Repairs have been completed, manufacturing operations have resumed, and ...
Breaking Medicine Technology: